Wednesday, October 14, 2026

Goldman Sachs Forecasts 7-Point ROE Drop for Big Tech as AI Capex Outpaces Revenue

Goldman Sachs published a report on June 12 projecting an average 7 percentage point decline in return on equity for Big Tech's largest companies over the next year. Microsoft, Alphabet, Meta, Amazon, and Apple are driving AI infrastructure spending at a pace that outstrips near-term revenue generation. AI hardware investment cycles typically lag revenue by 18 to 24 months, creating a structural margin pressure window through 2026 and 2027.

LM Salvado
LM Salvado

June 17, 2026

Goldman Sachs Forecasts 7-Point ROE Drop for Big Tech as AI Capex Outpaces Revenue
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Goldman Sachs forecasts a 7 percentage point decline in return on equity for Big Tech's largest companies over the next year, as AI infrastructure spending accelerates faster than revenue can follow.1

The report, published June 12, targets Microsoft, Alphabet, Meta, Amazon, and Apple — the five companies driving the bulk of AI capital expenditure. ROE compression is the projected result as these firms pour capital into data centers, chips, and AI infrastructure before monetization catches up.1

AI hardware and infrastructure investment cycles typically lag revenue generation by 18 to 24 months.1 That gap is the core risk. Companies are committing capital now; returns come later — if at all.

The S&P 500 has returned 9% year-to-date, driven largely by earnings growth.2 That performance assumes Big Tech profitability remains intact. Goldman's forecast challenges that assumption directly.

ROE measures how efficiently a company generates profit from shareholder equity. A 7-point decline is material. A company with 25% ROE dropping to 18% has meaningfully less to return to shareholders or reinvest in the business.

The five companies named represent a significant share of S&P 500 market capitalization. If their ROE falls in line with Goldman's projection, index-level earnings pressure would follow. Current valuations appear to price in continued profitability — not a margin contraction cycle.

The risk is structural. AI capex is not discretionary in the near term. Each company has made public commitments to infrastructure build-outs. Pulling back risks falling behind competitors. Pressing forward risks exactly the margin compression Goldman is warning about.

Revenue from AI — through cloud services, subscriptions, advertising, and enterprise tools — is growing, but not yet at the pace required to offset the capital being deployed. The 18-to-24-month investment-to-revenue lag makes 2026 and 2027 the likely pressure years.1

Investors tracking this trend should monitor quarterly ROE disclosures from Microsoft, Alphabet, Meta, Amazon, and Apple across the next four reporting cycles. A confirmed average decline in the 5 to 9 percentage point range would signal the thesis is materializing as Goldman projects.1

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com